Your session is about to expire
← Back to Search
Prescreening Group for Stargardt Disease
N/A
Recruiting
Research Sponsored by Ascidian Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
Summary
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Eligible Conditions
- Stargardt Disease
- Cone Rod Dystrophy
- Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Confirm mutations in the ABCA4 gene
Confirm the absence of pathogenic mutations in genes known to cause retinal disease other than ABCA4-related retinopathy
Historical BCVA/LLVA measurements
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Prescreening GroupExperimental Treatment1 Intervention
The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.
Find a Location
Who is running the clinical trial?
Ascidian Therapeutics, IncLead Sponsor
1 Previous Clinical Trials
13 Total Patients Enrolled
1 Trials studying Stargardt Disease
13 Patients Enrolled for Stargardt Disease
Alia RashidStudy DirectorAscidian Therapeutics
1 Previous Clinical Trials
13 Total Patients Enrolled
1 Trials studying Stargardt Disease
13 Patients Enrolled for Stargardt Disease
Share this study with friends
Copy Link
Messenger